Evidence map›Paper›PMID 31320597›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2019

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.

Patrick Y Wen, David A Reardon, Terri S Armstrong, Surasak Phuphanich, Robert D Aiken, Joseph C Landolfi, William T Curry, Jay-Jiguang Zhu, Michael Glantz, David M Peereboom and 13 more

Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 15 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 15 syntheses or guidelines pooled it, 266 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Review
  19. Review
  20. Article

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 20 institutions in 3 countries.

Patrick Y WenCenter For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. pwen@partners.org.
David A ReardonCenter For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Terri S ArmstrongNeuro-Oncology Branch, NCI, Bethesda, Maryland.
Surasak PhuphanichBarrow Neurological Institute, Phoenix, Arizona.
Robert D AikenRutgers-Cancer Institute of New Jersey, New Brunswick, New Jersey.
Joseph C LandolfiNew Jersey Neuroscience Institute, Edison, New Jersey.
William T CurryMassachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-8036-1847
Jay-Jiguang ZhuUniversity of Texas Health Sciences Center at Houston (UTHealth), Houston, Texas.ORCID 0000-0003-4635-0914
Michael GlantzPenn State Hershey Medical Center, Hershey, Pennsylvania.
David M PeereboomCleveland Clinic Lerner College of Medicine, Cleveland, Ohio.ORCID 0000-0001-7798-5176
James M MarkertUniversity of Alabama at Birmingham, Birmingham, Alabama.
Renato LaRoccaNorton Cancer Institute, Louisville, Kentucky.
Donald M O'RourkeRaymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Karen FinkBaylor Scott and White Neuro-Oncology Associates, Dallas, Texas.
Lyndon KimThomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Michael GruberNew York University, New York, New York.
Glenn J LesserWake Forest Baptist Medical Center, Winston-Salem, North Carolina.
Edward PanUniversity of Texas, Southwest Medical Center, Dallas, Texas.ORCID 0000-0002-2676-1639
Santosh KesariJohn Wayne Cancer Institute and Pacific Neuroscience Institute, Santa Monica, California.
Alona MuzikanskyAlona Muzikansky, Massachusetts General Hospital, Boston, Massachusetts.
Clemencia PinillaTorrey Pines Institute for Molecular Studies, Port St. Lucie, Florida.
Radleigh G SantosTorrey Pines Institute for Molecular Studies, Port St. Lucie, Florida.
John S YuCedars-Sinai Medical Center, Los Angeles, California.
Center for Neuro-Oncology · USMassachusetts General Hospital · USTorrey Pines Institute For Molecular Studies · USAtrium Health Wake Forest Baptist · USBarrow Neurological Institute · USBaylor Scott & White Health · USCedars-Sinai Medical Center · USCleveland Clinic Lerner College of Medicine · USJohn F. Kennedy Medical Center · USMaryland Oncology Hematology · USNorton Healthcare · USPenn State Milton S. Hershey Medical Center · USRutgers, The State University of New Jersey · USSaint John's Health Center · USThe University of Texas Health Science Center · USThe University of Texas Southwestern Medical Center · USThomas Jefferson University Hospital · USUniversity of Alabama at Birmingham · USUniversity of Pennsylvania · USYork University · CA

Funding

Natural History and Specimen Banking for Patients with CNS TumorsZIABC011768 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ARMSTRONG, TERRI S. · 2017 to 2024
$6.7M
Intramural NIH HHS ZIA BC011768
6 · The paper itself

Abstract

purposeTo evaluate the results of the randomized, double-blind, placebo-controlled phase II clinical trial of ICT-107 in patients with newly diagnosed glioblastoma. PATIENTS AND

methodsWe conducted a double-blinded randomized phase II trial of ICT-107 in newly diagnosed patients with glioblastoma (GBM) and tested efficacy, safety, quality of life (QoL), and immune response. HLA-A1

resultsICT-107 was well tolerated, with no difference in adverse events between the treatment and control groups. The primary endpoint, median overall survival (OS), favored ICT-107 by 2.0 months in the intent-to-treat (ITT) population but was not statistically significant. Progression-free survival (PFS) in the ITT population was significantly increased in the ICT-107 cohort by 2.2 months (

conclusionsPFS was significantly improved in ICT-107-treated patients with maintenance of QoL. Patients in the HLA-A2 subgroup showed increased ICT-107 activity clinically and immunologically.

Indexed as

AgedAntigens, NeoplasmAntineoplastic Agents, AlkylatingBrain NeoplasmsCancer VaccinesCohort StudiesDendritic CellsDisease-Free SurvivalDouble-Blind MethodFemaleGlioblastomaHumansMaleMiddle AgedQuality of LifeSurvival RateAntigens, NeoplasmAntineoplastic Agents, AlkylatingCancer VaccinesTemozolomide

Identifiers

PMID31320597
PMCPMC8132111
OpenAlexW2963730372

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.